Alexion

News

Akari soars ahead of read-out for Soliris rival

Investors are anticipating good news from a potential rival to Alexion’s rare disease blockbuster Soliris, with shares in the company behind it soaring.

News

Alexion appoints former Baxalta chief Hantson as CEO

Former AZ chief David Brennan expected to take over as chairman in May.

News

Pharma must slash rare disease drug prices - patient organis...

More rare disease drugs must also be approved, says EURORDIS.

News

NICE rejects second Alexion ultra-rare disease drug

NHS will not fund Kanuma for rare disease LAL-D.

News

Alexion lambasts NICE over rare disease ruling

Watchdog accused of ignoring stakeholder consensus and call for negotiations

News

No dishonest dealing in our sales reports, says Alexion

Shares rise following announcement.

Akari soars ahead of read-out for Soliris rival

Alexion appoints former Baxalta chief Hantson as CEO

Pharma must slash rare disease drug prices - patient organis...

NICE rejects second Alexion ultra-rare disease drug

Alexion lambasts NICE over rare disease ruling

No dishonest dealing in our sales reports, says Alexion

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Alexion

Editor's Picks